Cinaciguat

SKU: orb1306849

Description

Cinaciguat (BAY 58-2667) is a pioneering soluble guanylate cyclase (sGC) activator developed for treating acute decompensated heart failure. It is widely used in cardiovascular research to study sGC function and hemodynamics in both in vitro assays and in vivo heart failure models.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 329773-35-5
• MW: 565.7
• Purity: 98.00%
• Formula: C₃₆H₃₉NO₅
• SMILES: O(CC1=CC=C(CCC2=CC=CC=C2)C=C1)C3=C(CCN(CC4=CC=C(C(O)=O)C=C4)CCCCC(O)=O)C=CC=C3
• Target: Guanylate cyclase
• Solubility: DMSO:45 mg/mL (79.55 mM);10% DMSO+90% Corn Oil:2 mg/mL (3.54 mM)

Bioactivity

• In Vivo:
  Cinaciguat (10 mg/kg/day, p.o.) treatment in diabetic rats does not affect blood glucose levels but reduces water intake, alleviates diabetes mellitus-related oxidative stress, protects against alterations in the NO-sGC-cGMP-PKG signaling pathway, and reduces myocardium hypertrophy and apoptosis. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not influence phasic activity induced by PGF2α in WT or apo-sGC strips.
• In Vitro:
  Cinaciguat (10 μM) significantly enhances intracellular cGMP generation without exhibiting dose-dependent effects on cell contraction and calcium transients.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, Guanylatecyclase, guanylate cyclase, Guanylate Cyclase, Guanylate cyclase, Cinaciguat, BAY 58-2667

Compound Identifiers

PubChem CID

9808022